News | August 03, 2024
AbbVie completes acquisition of Cerevel Therapeutics
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
GSK and Flagship to jointly fund up to $150 million upfront
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
Campaign launched to spread awareness regarding dengue prevention and control
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Subscribe To Our Newsletter & Stay Updated
